Table 1 The clinical characteristics and outcome of ERA
Characteristics | (N = 160) |
|---|---|
Demographic characteristics | |
Male sex, n (%) | 83 (51.9) |
Age at onset, y | 9.2 ± 3.0 |
Duration from onset to diagnosis, m | 7.6 ± 12.4 |
Duration at follow-up visit, m | 18.4 ± 11.9 |
Disease characteristics | |
Peripheral arthritis at diagnosis, n (%) | 144 (90.0) |
AJC, n (IQR) | 2 (1, 4) |
Enthesitis, n (%) | 48 (30.0) |
Back Pain, n (%) | 36 (22.5) |
Family history, n (%) | 14 (8.6) |
A history of trauma, n (%) | 17 (10.6) |
Infection, n (%) | 8 (5.0) |
Uveitis, n (%) | 3 (1.9) |
Inflammatory bowel disease, n (%) | 0 (0) |
WBC, 10^9/L | 6.8 ± 2.0 |
ESR at diagnosis, mm/h | 22.4 ± 26.9 |
CRP at diagnosis, mg/L | 11.1 ± 26.9 |
TNF-a, pg/ml | 25.0 ± 49.7 |
HLA-B27 (+), n (%) | 33 (20.6) |
ANA (+), n (%) | 23 (14.4) |
RF (+), n (%) | 1 (0.6) |
FER, ug/L | 71.7 ± 73.3 |
IgG, g/L | 12.0 ± 3.3 |
IgA, g/L | 1.7 ± 0.9 |
IgM, g/L | 1.3 ± 0.6 |
IgE, g/L | 180.8 ± 343.9 |
JSpADA | 2.3 ± 0.73 |
Mediation | |
NSAIDs, n (%) | 43 (26.8) |
Steroids, n (%) | 12 (7.5) |
Intraarticular steroids injection, n (%) | 1 (0.6) |
Methotrexate, n (%) | 109 (68.1) |
Sulfasalazine, n (%) | 48 (30.0) |
Leflunomide, n (%) | 11 (6.9) |
Biologics, n (%) | 96 (60.0) |
DMARDs + Biologics, n (%) | 91 (56.9) |